159 related articles for article (PubMed ID: 26529521)
1. Growth in Boys with 45,X/46,XY Mosaicism: Effect of Growth Hormone Treatment on Statural Growth.
Bertelloni S; Baroncelli GI; Massart F; Toschi B
Sex Dev; 2015; 9(4):183-9. PubMed ID: 26529521
[TBL] [Abstract][Full Text] [Related]
2. 45,X/46,XY mosaicism: phenotypic characteristics, growth, and reproductive function--a retrospective longitudinal study.
Lindhardt Johansen M; Hagen CP; Rajpert-De Meyts E; Kjærgaard S; Petersen BL; Skakkebæk NE; Main KM; Juul A
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1540-9. PubMed ID: 22605431
[TBL] [Abstract][Full Text] [Related]
3. Short stature in children with an apparently normal male phenotype can be caused by 45,X/46,XY mosaicism and is susceptible to growth hormone treatment.
Richter-Unruh A; Knauer-Fischer S; Kaspers S; Albrecht B; Gillessen-Kaesbach G; Hauffa BP
Eur J Pediatr; 2004 Apr; 163(4-5):251-6. PubMed ID: 14986122
[TBL] [Abstract][Full Text] [Related]
4. 45,X/46,XY mosaicism: a cause of short stature in males.
Efthymiadou A; Stefanou EG; Chrysis D
Hormones (Athens); 2012; 11(4):501-4. PubMed ID: 23422775
[TBL] [Abstract][Full Text] [Related]
5. Long-term growth hormone treatment in a boy with 45,X/46,X,idic(Yp) mixed gonadal dysgenesis: comparison with growth pattern of an untreated patient.
Bertelloni S; Dati E; Valetto A; Bertini V; Danti A; Baroncelli GI
Hormones (Athens); 2015; 14(1):142-7. PubMed ID: 25402381
[TBL] [Abstract][Full Text] [Related]
6. Short stature in patients with 45,X/46,XY mosaicism: report of three cases.
Lee CF; Su PH; Chen JY; Chen SJ; Yang KC; Lin LL
Acta Paediatr Taiwan; 2006; 47(6):312-6. PubMed ID: 17407984
[TBL] [Abstract][Full Text] [Related]
7. 45,X/46,XY Mosaicism Presenting With Isolated Unilateral Cryptorchidism and a Normal Blood Karyotype.
Morandi G; Cerbone M; Lamback EB; Rapti E; Dattani MT
J Clin Endocrinol Metab; 2018 Jun; 103(6):2079-2082. PubMed ID: 29618062
[TBL] [Abstract][Full Text] [Related]
8. The spectrum of 45,X/46,XY mosaicism in Taiwanese children: The experience of a single center.
Huang YC; Lee CT; Wu MZ; Liu SY; Tung YC; Ho HN; Tsai WY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):450-456. PubMed ID: 30017534
[TBL] [Abstract][Full Text] [Related]
9. Safety of growth hormone treatment in pediatric patients with idiopathic short stature.
Quigley CA; Gill AM; Crowe BJ; Robling K; Chipman JJ; Rose SR; Ross JL; Cassorla FG; Wolka AM; Wit JM; Rekers-Mombarg LT; Cutler GB
J Clin Endocrinol Metab; 2005 Sep; 90(9):5188-96. PubMed ID: 15899952
[TBL] [Abstract][Full Text] [Related]
10. Growth and growth hormone treatment in short stature children born small for gestational age.
Labarta JI; Ruiz JA; Molina I; De Arriba A; Mayayo E; Longás AF
Pediatr Endocrinol Rev; 2009 Feb; 6 Suppl 3():350-7. PubMed ID: 19404234
[TBL] [Abstract][Full Text] [Related]
11. 45,X/46,XY mosaicism. A clinical review and report of ten cases.
Knudtzon J; Aarskog D
Eur J Pediatr; 1987 May; 146(3):266-71. PubMed ID: 3595646
[TBL] [Abstract][Full Text] [Related]
12. Children with 45,X/46,XY karyotype from birth to adult height.
Tosson H; Rose SR; Gartner LA
Horm Res Paediatr; 2010; 74(3):190-200. PubMed ID: 20431272
[TBL] [Abstract][Full Text] [Related]
13. Should 45,X/46,XY boys with no or mild anomaly of external genitalia be investigated and followed up?
Dumeige L; Chatelais L; Bouvattier C; De Kerdanet M; Hyon C; Esteva B; Samara-Boustani D; Zenaty D; Nicolino M; Baron S; Metz-Blond C; Naud-Saudreau C; Dupuis C; Léger J; Siffroi JP; Donadille B; Christin-Maitre S; Carel JC; Coutant R; Martinerie L
Eur J Endocrinol; 2018 Sep; 179(3):181-190. PubMed ID: 29973376
[TBL] [Abstract][Full Text] [Related]
14. Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45,X/46,XY mosaicism.
Cools M; Pleskacova J; Stoop H; Hoebeke P; Van Laecke E; Drop SL; Lebl J; Oosterhuis JW; Looijenga LH; Wolffenbuttel KP;
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1171-80. PubMed ID: 21508138
[TBL] [Abstract][Full Text] [Related]
15. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
[TBL] [Abstract][Full Text] [Related]
16. Growth data and tumour risk of 32 Chinese children and adolescents with 45,X/46,XY mosaicism.
Pan L; Su Z; Song J; Xu W; Liu X; Zhang L; Li S;
BMC Pediatr; 2019 May; 19(1):143. PubMed ID: 31060547
[TBL] [Abstract][Full Text] [Related]
17. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome.
Blum WF; Cao D; Hesse V; Fricke-Otto S; Ross JL; Jones C; Quigley CA; Binder G
Horm Res; 2009; 71(3):167-72. PubMed ID: 19188742
[TBL] [Abstract][Full Text] [Related]
18. Analyses from a centre of short- and long-term growth in Turner's syndrome on standard growth hormone doses confirm growth prediction algorithms and show normal IGF-I levels.
Ranke MB; Schweizer R; Martin DD; Ehehalt S; Schwarze CP; Serra F; Binder G
Horm Res Paediatr; 2012; 77(4):214-21. PubMed ID: 22433161
[TBL] [Abstract][Full Text] [Related]
19. X-chromosome gene dosage as a determinant of impaired pre and postnatal growth and adult height in Turner syndrome.
Fiot E; Zenaty D; Boizeau P; Haigneré J; Dos Santos S; Léger J;
Eur J Endocrinol; 2016 Mar; 174(3):281-8. PubMed ID: 26744895
[TBL] [Abstract][Full Text] [Related]
20. Why Treat girls with Turner Syndrome with Growth Hormone? Growth and Beyond.
Ranke MB
Pediatr Endocrinol Rev; 2015 Jun; 12(4):356-65. PubMed ID: 26182480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
